Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
July 11, 2022
Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Authored By: Meng Zhu, Yaping Chang, Steve Phillips, Ellen Scholl, Selina Bains, Mohit Bhandari on behalf of OrthoEvidence
Highlights
- In the present OE Original, we conduct a systematic review and meta-analysis to examine evidence from randomized controlled trials (RCTs) comparing the efficacy and safety of tanezumab (2.5 mg or 5 mg) administered intravenously or subcutaneously with oral non-steroidal anti-inflammatory drugs (NSAIDs) in patients with hip or knee osteoarthritis (OA).
- Six studies, representing 4 RCT cohorts, were identified. All studies were sponsored by Pfizer.
- Tanezumab 2.5 mg significantly improved WOMAC pain, WOMAC function, and PGA only at 4 weeks post treatment, but not at 16 weeks after treatment. In addition, tanezumab 2.5 mg resulted in an elevated risk of developing rapidly progressive OA, compared to NSAIDs.
- Tanezumab 5 mg, more efficacious than 2.5 mg tanezumab, markedly improved all efficacy outcomes at both 4 weeks and 16 weeks post treatment. However, such benefits might not be clinically important. More importantly, tanezumab 5 mg raised more safety concerns: it significantly increased the risk of developing any adverse event, rapidly progressive OA, and abnormal peripheral sensation, compared to oral NSAIDs.
- There lacks convincing evidence demonstrating that the benefits of tanezumab 2.5 mg or 5 mg outweigh the harms.
To view the full content, login to your account,
FREE TRIAL LOGIN Forgot Password?SHARE THIS OE ORIGINAL
Loading...
Join the Conversation
Please Login or Join to leave comments.
Orthopaedic Surgeon - Canada
Very disappointing longer term findings after a promising start.So many studies copy this direction: steroid injections, partiai meniscectomies etc. The role of more modern regenerative medicine needs deeper study than any done so far by OE.